Angle's Parsortix System Gets U.S. Approval; Shares Jump
May 25 2022 - 8:20AM
Dow Jones News
By Ian Walker
Shares of Angle PLC rose 24% on Wednesday after the company said
that the U.S. Food and Drug Administration has cleared its
Parsortix system for patients with metastatic breast cancer.
Shares at 1139 GMT were up 24.0 pence at 122.50 pence.
The U.K. liquid-biopsy company's Parsortix system harvests
cancer cells from blood for analysis.
"This ground-breaking, first-ever FDA product clearance in
metastatic breast cancer provides the platform for Angle to work
with our collaborators and customers to support further FDA
submissions and the establishment of numerous specific clinical
uses across different cancer types," Founder and Chief Executive
Andrew Newland said.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
May 25, 2022 08:05 ET (12:05 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024